Ifp Advisors, Inc Prothena Corp Public LTD CO Transaction History

Ifp Advisors, Inc

$2.91 Billion
Q4 2024

A detailed history of Ifp Advisors, Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Ifp Advisors, Inc holds 132 shares of PRTA stock, worth $1,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares

132

Holding current value

$1,214

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$11.95 - $18.35 $1,577 - $2,422	132 New	132 $1,000
Q3 2021 Oct 06, 2021	SELL	$48.2 - $78.89 $964 - $1,577	-20 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$21.63 - $57.65 $21 - $57	1 Added 5.26%	20 $1,000
Q1 2021 Apr 30, 2021	BUY	$11.0 - $28.24 $22 - $56	2 Added 11.76%	19 $0
Q4 2020 Jan 25, 2021	SELL	$10.12 - $13.94 $192 - $264	-19 Reduced 52.78%	17 $0
Q3 2020 Oct 29, 2020	BUY	$9.93 - $13.47 $357 - $484	36 New	36 $0
Q2 2020 Aug 05, 2020	BUY	$9.56 - $12.51 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$7.54 - $15.77 $0 - $0	0 New	0 $0
Q4 2018 Jan 23, 2019	SELL	$8.73 - $13.74 $8 - $13	-1 Closed	0 $0
Q4 2017 Jan 24, 2018	SELL	$35.44 - $63.76 $141 - $255	-4 Reduced 80.0%	1 $0
Q2 2017 Jun 03, 2019	BUY	N/A	1 Added 25.0%	5 $0
Q2 2016 Jun 03, 2019	BUY	N/A	4	4 $0

Others Institutions Holding PRTA

# of Institutions

197

Shares Held

39.4M

Call Options Held

601K

Put Options Held

259K

Eco R1 Capital, LLC San Francisco, CA

11.6M
Shares

$107 Million
7.5% of portfolio
Black Rock Inc. New York, NY

3.86M
Shares

$35.5 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.69M
Shares

$33.9 Million
0.01% of portfolio
Armistice Capital, LLC New York, NY

2.24M
Shares

$20.6 Million
0.44% of portfolio
State Street Corp Boston, MA

1.86M
Shares

$17.1 Million
0.0% of portfolio

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $432M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account